TMS Stroke Deal Suggests No Big Buy From Biogen Yet
The investment community has been willing Biogen to make a big deal for some time now but a modest pact inked with Japan's TMS for its Phase II acute ischemic stroke drug suggests that management will continue to favor picking up promising compounds rather than diving into major M&A.
You may also be interested in...
Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out
The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.
Biogen’s Q2 Highlights Need For Near-Term Successes
Second quarter performance was better than expected, but commercial weaknesses show the need for R&D wins and M&A deals as Tecfidera generics and aducanumab uncertainty weigh on the company.
Eisai/Biogen Remain In BACE Race As Alzheimer's Contenders Dwindle
Multiple competitors have ended development of BACE inhibitors for the treatment of Alzheimer's disease, but Eisai neurology executive Lynn Kramer tells Scrip that the company still sees a path forward for certain amyloid-targeting drugs.